Cell therapy developer Lyell Immunopharma initiated a head‑to‑head CAR‑T trial that will compare its experimental product directly against marketed CAR‑T therapies. The trial structure is novel for the field and aims to generate comparative efficacy and safety data that could accelerate clinical adoption. Lyell’s design reflects a growing trend among cell therapy companies to prove superiority or clear niche benefits over established products. The study will be closely watched for trial conduct, endpoints selected, and implications for reimbursement and clinician choice if Lyell’s candidate demonstrates clinical or operational advantages.